Targeted PET imaging strategy to differentiate malignant from inflamed lymph nodes in diffuse large B-cell lymphoma

Jun Tang, Darin Salloum, Brandon Carney, Christian Brand, Susanne Kossatz, Ahmad Sadique, Jason S. Lewis, Wolfgang A. Weber, Hans Guido Wendel, Thomas Reiner

Research output: Contribution to journalArticlepeer-review

27 Scopus citations

Abstract

Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma in adults. DLBCL exhibits highly aggressive and systemic progression into multiple tissues in patients, particularly in lymph nodes. Whole-body 18F-fluodeoxyglucose positron emission tomography ([18F]FDG-PET) imaging has an essential role in diagnosing DLBCL in the clinic; however, [18F]FDG-PET often faces difficulty in differentiating malignant tissues from certain nonmalignant tissues with high glucose uptake. We have developed a PET imaging strategy for DLBCL that targets poly[ADP ribose] polymerase 1 (PARP1), the expression of which has been found to be much higher in DLBCL than in healthy tissues. In a syngeneic DLBCL mouse model, this PARP1-targeted PET imaging approach allowed us to discriminate between malignant and inflamed lymph nodes, whereas [18F]FDG-PET failed to do so. Our PARP1-targeted PET imaging approach may be an attractive addition to the current PET imaging strategy to differentiate inflammation from malignancy in DLBCL.

Original languageEnglish
Pages (from-to)E7441-E7449
JournalProceedings of the National Academy of Sciences of the United States of America
Volume114
Issue number36
DOIs
StatePublished - 5 Sep 2017
Externally publishedYes

Keywords

  • Diffuse large B-cell lymphoma
  • Inflammation
  • PARP1
  • PET/CT
  • [F]PARPi

Fingerprint

Dive into the research topics of 'Targeted PET imaging strategy to differentiate malignant from inflamed lymph nodes in diffuse large B-cell lymphoma'. Together they form a unique fingerprint.

Cite this